A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma
| Title | A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma |
|---|---|
| Description | Abstract for ASCO GI 2023 |
| Organism | Homo sapiens |
| Data Type | Other Type of Clinical information |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA011366 |
| Release Date | 2023-01-17 |
| Submitter | Jianming Xu (jianmingxu2014@163.com) |
| Organization | Chinese PLA General Hospital (CPLAGH) |
| Submission Date | 2022-11-28 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX002466-03 | Result table of Abstract for ASCO GI 2023 | 1 | Other Type of Clinical information | 164.3 KB | 0 | Controlled |